ArticleMycoses2026
A Multifactorial Azole Response in Clinically Relevant Fusarium Species Complexes.
Article in Mycoses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundFusarium spp. are clinically relevant filamentous fungi with intrinsically low susceptibility to multiple antifungal agents, particularly azoles, and are included in the World Health Organization fungal priority pathogens list.
objectivesTo investigate azole resistance-related mechanisms in clinical isolates belonging to the Fusarium solani species complex (FSSC), Fusarium oxysporum species complex (FOSC) and Fusarium fujikuroi species complex (FFSC) recovered in São Paulo, Brazil.
methodsTwenty-six clinical isolates were identified by sequencing of the ITS region, TEF1 and RPB2. Antifungal susceptibility testing, CYP51A amplification and sequencing and expression analysis of CYP51A and ABC1 under voriconazole exposure were performed.
resultsAntifungal susceptibility testing showed broadly elevated azole MICs, with the FSSC displaying the least favourable profile. Comparative CYP51A analysis revealed distinct amino acid signatures among the three species complexes, including residues at positions equivalent to canonical azole resistance hotspots in Aspergillus fumigatus. However, no simple relationship was observed between CYP51A amino acid profiles and azole MIC values. In contrast, voriconazole exposure induced marked CYP51A upregulation in all tested isolates, with substantially higher expression in the higher-MIC FSSC isolate. ABC1 was also upregulated in FSSC isolates, although at markedly lower levels than CYP51A.
conclusionsThese findings support a multifactorial model of azole response in Fusarium species complex strains, involving conserved CYP51A sequence features, strong target-gene induction under antifungal stress, and a lower but detectable contribution of efflux-associated mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.